{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cytocinèse : Questions médicales les plus fréquentes",
"headline": "Cytocinèse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cytocinèse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-25",
"dateModified": "2025-04-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cytocinèse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cycle cellulaire",
"url": "https://questionsmedicales.fr/mesh/D002453",
"about": {
"@type": "MedicalCondition",
"name": "Cycle cellulaire",
"code": {
"@type": "MedicalCode",
"code": "D002453",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G04.144"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cytocinèse",
"alternateName": "Cytokinesis",
"code": {
"@type": "MedicalCode",
"code": "D048749",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Anna Tetkova",
"url": "https://questionsmedicales.fr/author/Anna%20Tetkova",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Biochemistry and Molecular Biology of Germ Cells, IAPG CAS, Libechov, Czech Republic."
}
},
{
"@type": "Person",
"name": "Denisa Jansova",
"url": "https://questionsmedicales.fr/author/Denisa%20Jansova",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Biochemistry and Molecular Biology of Germ Cells, IAPG CAS, Libechov, Czech Republic."
}
},
{
"@type": "Person",
"name": "Andrej Susor",
"url": "https://questionsmedicales.fr/author/Andrej%20Susor",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Biochemistry and Molecular Biology of Germ Cells, IAPG CAS, Libechov, Czech Republic. susor@iapg.cas.cz."
}
},
{
"@type": "Person",
"name": "Thomas D Pollard",
"url": "https://questionsmedicales.fr/author/Thomas%20D%20Pollard",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular, Cellular and Developmental Biology, Department of Molecular Biophysics and Biochemistry, Department of Cell Biology, Yale University, New Haven, CT, USA. thomas.pollard@yale.edu."
}
},
{
"@type": "Person",
"name": "Susanne M A Lens",
"url": "https://questionsmedicales.fr/author/Susanne%20M%20A%20Lens",
"affiliation": {
"@type": "Organization",
"name": "Oncode Institute, Utrecht, Netherlands. s.m.a.lens@umcutrecht.nl."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Postoperative venous thromboembolism after surgery for locally recurrent rectal cancer.",
"datePublished": "2024-08-20",
"url": "https://questionsmedicales.fr/article/39164626",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-024-12799-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.",
"datePublished": "2023-01-31",
"url": "https://questionsmedicales.fr/article/36720507",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1759-7714.14805"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development of a consensus-based delineation guideline for locally recurrent rectal cancer.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36410547",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.radonc.2022.11.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary.",
"datePublished": "2022-08-08",
"url": "https://questionsmedicales.fr/article/35939185",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10549-022-06680-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimal surveillance of intraductal papillary mucinous neoplasms of the pancreas focusing on remnant pancreas recurrence after surgical resection.",
"datePublished": "2022-05-29",
"url": "https://questionsmedicales.fr/article/35643422",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-022-09650-w"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques cellulaires",
"item": "https://questionsmedicales.fr/mesh/D002468"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cycle cellulaire",
"item": "https://questionsmedicales.fr/mesh/D002453"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cytocinèse",
"item": "https://questionsmedicales.fr/mesh/D048749"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cytocinèse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cytocinèse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cytocinèse",
"description": "Comment diagnostiquer une anomalie de cytocinèse ?\nQuels examens sont utilisés pour étudier la cytocinèse ?\nQuels marqueurs cellulaires indiquent une cytocinèse réussie ?\nPeut-on observer la cytocinèse au microscope ?\nQuels sont les signes d'une cytocinèse défectueuse ?",
"url": "https://questionsmedicales.fr/mesh/D048749?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cytocinèse",
"description": "Quels symptômes indiquent une défaillance de la cytocinèse ?\nLa cytocinèse affecte-t-elle la croissance cellulaire ?\nQuels effets sur les tissus peuvent résulter d'une mauvaise cytocinèse ?\nY a-t-il des symptômes associés à des troubles de la cytocinèse ?\nComment la cytocinèse influence-t-elle le cycle cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D048749?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cytocinèse",
"description": "Peut-on prévenir les troubles de la cytocinèse ?\nQuels facteurs de style de vie influencent la cytocinèse ?\nLes toxines environnementales affectent-elles la cytocinèse ?\nComment le stress influence-t-il la cytocinèse ?\nLes infections peuvent-elles perturber la cytocinèse ?",
"url": "https://questionsmedicales.fr/mesh/D048749?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cytocinèse",
"description": "Quels traitements existent pour les troubles de la cytocinèse ?\nPeut-on corriger les anomalies de la cytocinèse ?\nQuels médicaments affectent la cytocinèse ?\nLa thérapie génique peut-elle aider la cytocinèse ?\nComment la recherche aide-t-elle à traiter les troubles de la cytocinèse ?",
"url": "https://questionsmedicales.fr/mesh/D048749?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cytocinèse",
"description": "Quelles complications peuvent résulter d'une cytocinèse défectueuse ?\nComment la cytocinèse affecte-t-elle le développement embryonnaire ?\nLes troubles de la cytocinèse sont-ils héréditaires ?\nQuels cancers sont liés à des anomalies de la cytocinèse ?\nLa cytocinèse défectueuse peut-elle affecter le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D048749?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cytocinèse",
"description": "Quels facteurs génétiques influencent la cytocinèse ?\nL'âge est-il un facteur de risque pour la cytocinèse ?\nLes habitudes alimentaires affectent-elles la cytocinèse ?\nLe tabagisme influence-t-il la cytocinèse ?\nLes expositions professionnelles peuvent-elles affecter la cytocinèse ?",
"url": "https://questionsmedicales.fr/mesh/D048749?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de cytocinèse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de microscopie et des analyses génétiques peuvent révéler des anomalies."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour étudier la cytocinèse ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "La microscopie à fluorescence et l'immunofluorescence sont couramment utilisées."
}
},
{
"@type": "Question",
"name": "Quels marqueurs cellulaires indiquent une cytocinèse réussie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La présence de structures comme le sillon de division et les corps de Golgi est observée."
}
},
{
"@type": "Question",
"name": "Peut-on observer la cytocinèse au microscope ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la cytocinèse est visible au microscope lors de la division cellulaire."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une cytocinèse défectueuse ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cellules multinucleées ou des anomalies morphologiques peuvent indiquer des problèmes."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une défaillance de la cytocinèse ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cellules anormales, comme des cellules géantes, peuvent être observées."
}
},
{
"@type": "Question",
"name": "La cytocinèse affecte-t-elle la croissance cellulaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une cytocinèse défectueuse peut ralentir ou bloquer la croissance cellulaire."
}
},
{
"@type": "Question",
"name": "Quels effets sur les tissus peuvent résulter d'une mauvaise cytocinèse ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela peut entraîner des malformations tissulaires et des troubles fonctionnels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés à des troubles de la cytocinèse ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles comme le cancer peuvent être liés à des anomalies de la cytocinèse."
}
},
{
"@type": "Question",
"name": "Comment la cytocinèse influence-t-elle le cycle cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est essentielle pour terminer le cycle cellulaire et permettre la division."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles de la cytocinèse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne santé cellulaire et des habitudes de vie saines peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Quels facteurs de style de vie influencent la cytocinèse ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier favorisent la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Les toxines environnementales affectent-elles la cytocinèse ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut perturber la cytocinèse."
}
},
{
"@type": "Question",
"name": "Comment le stress influence-t-il la cytocinèse ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut affecter la division cellulaire et la cytocinèse."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles perturber la cytocinèse ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent interférer avec le processus de cytocinèse."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les troubles de la cytocinèse ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements ciblent souvent les causes sous-jacentes, comme la chimiothérapie."
}
},
{
"@type": "Question",
"name": "Peut-on corriger les anomalies de la cytocinèse ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent être corrigées par des thérapies géniques expérimentales."
}
},
{
"@type": "Question",
"name": "Quels médicaments affectent la cytocinèse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agents comme la colchicine peuvent perturber la cytocinèse en bloquant la mitose."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle aider la cytocinèse ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut corriger certaines mutations affectant la cytocinèse."
}
},
{
"@type": "Question",
"name": "Comment la recherche aide-t-elle à traiter les troubles de la cytocinèse ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La recherche explore de nouvelles cibles thérapeutiques pour améliorer la cytocinèse."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter d'une cytocinèse défectueuse ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des malformations et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Comment la cytocinèse affecte-t-elle le développement embryonnaire ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une cytocinèse anormale peut entraîner des malformations congénitales."
}
},
{
"@type": "Question",
"name": "Les troubles de la cytocinèse sont-ils héréditaires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent être héréditaires, augmentant le risque de maladies."
}
},
{
"@type": "Question",
"name": "Quels cancers sont liés à des anomalies de la cytocinèse ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers comme le cancer du sein et le cancer colorectal peuvent être liés."
}
},
{
"@type": "Question",
"name": "La cytocinèse défectueuse peut-elle affecter le système immunitaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut compromettre la fonction immunitaire et augmenter les infections."
}
},
{
"@type": "Question",
"name": "Quels facteurs génétiques influencent la cytocinèse ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mutations dans des gènes régulateurs peuvent augmenter le risque de troubles."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour la cytocinèse ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque d'anomalies dans la cytocinèse."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires affectent-elles la cytocinèse ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut réduire les risques d'anomalies."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la cytocinèse ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour des anomalies cellulaires."
}
},
{
"@type": "Question",
"name": "Les expositions professionnelles peuvent-elles affecter la cytocinèse ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines expositions à des produits chimiques peuvent perturber la cytocinèse."
}
}
]
}
]
}
Local recurrence is common after curative resections of rectal cancer. Surgical resection is considered a primary curative treatment option for patients with locally recurrent rectal cancer (LRRC). LR...
From April 2010 to March 2022, a total of 166 patients underwent surgery for LRRC in the pelvic region at our institutions. Clinicopathological background and VTE incidence were compared retrospective...
Among the 166 patients included in the study, 55 patients (33.1%) needed sacral resection. Pharmacological prophylaxis for prevention of VTE was performed in 121 patients (73.3%), and the incidence of...
This study demonstrates that surgery for LRRC combined with sacral resection could be a significant risk factor for VTE....
The effectiveness of local therapy has been reported in patients with oligo-recurrence of non-small cell lung cancer (NSCLC), a metachronous recurrence with a limited number of recurrences, which can ...
From 2004 to 2014, 811 patients underwent complete resection for NSCLC at Kitasato University Hospital and, of these, 244 patients developed recurrence. Oligo-recurrence was defined as the presence of...
We retrospectively examined and compared the effects of EGFR-TKIs with those of radical local therapy in patients with oligo-recurrent EGFR-mutated NSCLC. The five-year post-recurrence survival (PRS) ...
Radical local therapy did not affect PRS in patients with oligo-recurrent EGFR-mutated NSCLC. Even in cases of oligo-recurrence, the administration of local therapy in patients with EGFR-mutated NSCLC...
Neoadjuvant chemoradiotherapy (nCRT) is used in locally recurrent rectal cancer (LRRC) to increase chances of a radical surgical resection. Delineation in LRRC is hampered by complex disease presentat...
Eight radiation oncologists, from Dutch and Swedish expert centres, participated in two meetings, delineating GTV and CTV in six cases. Regions at-risk for re-recurrence or irradical resection were id...
Inter-observer variation in delineation of LRRC appeared large. Multidisciplinary evaluation per case is beneficial in determining target volumes. The following consensus regarding target volumes was ...
This study provides a first consensus-based delineation guideline for LRRC. Analyses of re-recurrences is needed to understand disease behaviour and to optimize delineation guidelines accordingly....
Describes the relevance of -various classification methods for ipsilateral breast tumour recurrence (IBTR) as either true recurrence (TR) or new primary (NP) on both disease-specific survival (DSS) an...
Two hundred and thirty-four of 4359 women undergoing breast-conserving therapy experienced IBTR. We compared the impact of four known classification methods and two newly created classification method...
For three of the methods, a better DSS was observed for NP compared to TR with the hazard ratio (HR) ranging from 0.5 to 0.6. The new Twente method classification, comprising all classification criter...
IBTR classified as TR or NP has a prognostic value for both DSS and DMFS, but depends on the classification method used. Developing and validating a generally accepted form of classification are imper...
The international consensus guidelines for intraductal papillary mucinous neoplasm of the pancreas (IPMN) presented clinical features as indications for surgery. Whereas surveillance for recurrence, i...
This study aimed to assess the clinical features of recurrence at the remnant pancreas (Rem-Panc) and extra-pancreas (Ex-Panc) after surgery for IPMN. Ninety-one patients of IPMN that underwent detail...
The IPMNs were finally diagnosed as low-grade dysplasia (LDA, n = 42), high-grade dysplasia (HAD, n = 19), and invasive carcinoma (IPMC, n = 30). Recurrence was observed in 26 patients (29%), of which...
The risk factors for Rem-Panc and Ex-Panc recurrence differ. Therefore, optimal surveillance on these features is desirable to ensure that repeat pancreatectomy for Rem-Panc recurrence can be an appro...
Postradiation treatment necrosis is one of the most serious late sequelae and appears within 6 months. The magnetic resonance spectroscopy imaging (MRSI) has been used for the detection of brain tumor...
The research was performed in accordance with the preferred reporting items for systematic review and meta-analysis guidelines. International electronic databases including 15 English sources were inv...
Nine studies were enrolled in the meta-analysis with a total of 354 patients (203 male and 151 female) whose average age ranged from 4 to 74 years. Anbarloui et al., Elias et al., Nemattalla et al., S...
MR spectroscopy is effective in distinguishing recurrent brain tumors from necrosis. Our meta-analysis revealed that Cho/NAA, Cho/Cr, and NAA/Cr ratios were significantly better predictor of detected ...
Despite multimodal therapy 5-15% of patients who undergo resection for advanced rectal cancer (LARC) will develop local recurrence. Management of locally recurrent rectal cancer (LRRC) presents a sign...
A systematic review was carried out searching MEDLINE, EMBASE and COCHRANE Trials database for all studies assessing pathological factors influencing survival following pelvic exenteration for LARC or...
Nine cohort studies met inclusion criteria, reporting outcomes for 2864 patients. Meta-analysis was not possible due to significant heterogeneity of reported outcomes. Resection margin status and noda...
Pathological resection margin status is widely demonstrated to influence disease free and overall survival following pelvic exenteration for rectal cancer. With increasing R0 rates, other adverse tumo...
A first pilot study showed that an image-guided navigation system could improve resection margin rates in locally advanced (LARC) and locally recurrent rectal cancer (LRRC) patients. Incremental surgi...
A Markov decision model was constructed to estimate the expected costs and outcomes for navigated and standard surgery. The input parameters were based on pilot data from a prospective (navigation coh...
Based on this early evaluation, navigated surgery showed incremental costs of €3141 and €2896 in LARC and LRRC. In LARC, navigated surgery resulted in 2.05 Quality-Adjusted Life Years (QALYs) vs 2.02 ...
Adding navigation system use is expected to be cost-effective in LRRC and has the potential to become cost-effective in LARC. To increase the probability of being cost-effective, it is crucial to opti...
Local recurrent brain metastases are defined as lesions that recur in the brain at the same site after a previous local therapy. In patients already submitted to surgery, a second operation may be pot...
37 patients submitted to surgery for a local, histologically confirmed, recurrent brain metastases between 2000 and 2022 were retrospectively analyzed with respect to the following parameters: age, hi...
A significant improvement of post-operative KPS status was obtained after second surgery. At multivariate analysis better results in terms of OS were achieved in patients with a pre-operative KPS ≥ 70...
Surgical resection of local recurrent brain metastases may improve patients ́ neurologic conditions allowing more time for systemic therapies to act with a low incidence of surgery-related morbidity a...
The management of locally recurrent gynecological carcinoma remains a challenge due to the limited availability of data. This study aims to share our institutional experience in using definitive radio...
The study retrospectively reviewed 20 patients in our hospital completing salvage 3D image-based HDR brachytherapy, with or without EBRT, for locally recurrent cervical and endometrial carcinoma after...
During a median observation period of 21 months, the study reported a tumor objective response rate of 95%. The 3-year DFS and OS rates were 89.4% and 90.9%, respectively. The EBRT combined with brach...
3D image-guided brachytherapy combined with EBRT shows effective tumor control and acceptable toxicity profile for women with locally recurrent gynecologic cancer. The success in managing vaginal recu...
